Movano Health Granted Listing Extension by Nasdaq
MWN-AI** Summary
Movano Health, a healthcare technology company specializing in wearable medical devices, has received a crucial extension from the Nasdaq Hearings Panel to maintain its public listing on the Nasdaq stock exchange. The decision, communicated on August 27, 2025, follows a hearing where the Panel assessed Movano’s strategies to comply with Nasdaq’s listing requirements.
To remain listed, Movano Health must meet two key conditions by specific deadlines. Firstly, the company is required to file its overdue Quarterly Reports on Form 10-Q for the quarters ending March 31 and June 30, 2025, by September 30, 2025. Secondly, it must ensure its share price meets or exceeds the $1.00 bid price regulation by October 30, 2025.
Movano Health has been actively collaborating with a new auditor to expedite the submission of the necessary filings and is optimistic about meeting these deadlines. Additionally, in preparation for its Annual Shareholders Meeting scheduled for September 26, 2025, the company filed a Preliminary Proxy Statement proposing a reverse stock split. This action aims to facilitate compliance with the bid price requirement, thereby enhancing its chances of sustaining its Nasdaq listing.
Founded in 2018, Movano Health focuses on creating innovative health-monitoring solutions, including its flagship product, the Evie Ring, which offers users a comprehensive view of their health data through cutting-edge wearable technology. As the company progresses, it emphasizes its commitment to delivering reliable health insights that can improve patient outcomes across various demographics.
Despite the current challenges, Movano Health’s proactive approach and strategic planning foster hope for the company’s continued presence on the Nasdaq and its mission to enhance healthcare through wearable technology.
MWN-AI** Analysis
Movano Health's recent announcement regarding the granting of a listing extension by Nasdaq provides a critical juncture for investors to evaluate their position in this innovative health-focused technology company. The extension gives Movano Health until September 30, 2025, to file its overdue quarterly reports, and until October 30, 2025, to maintain its share price above $1.00, as stipulated by Nasdaq Listing Rules.
From a market perspective, the company's efforts to regain compliance with the Period Filing Rule and the Bid Price Rule signal a proactive approach to governance and transparency. However, the execution of this plan is paramount. Investors should take note that while the approval of a reverse stock split could strategically elevate the share price, it may also lead to volatility in the stock during the transition period. A reverse stock split can be a double-edged sword, potentially improving compliance metrics but also feeding concerns among investors about the underlying financial health of the company.
The upcoming Annual Shareholders Meeting on September 26, 2025, offers an important opportunity for investors to express their confidence or skepticism regarding management's strategies. The company's recent work with a new auditor underscores a commitment to rectifying past compliance issues, yet investors must remain cautious, as any delays in filings or underwhelming performance in meeting the Nasdaq standards could result in significant financial ramifications.
In conclusion, while Movano Health's strategic steps toward compliance present a potential turnaround opportunity, investors should closely monitor the execution of these plans. Assessing risk factors, including potential delays and the reception of reverse stock split proposals at the shareholder meeting, will be key to making informed investment decisions in the volatile landscape of health tech securities.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
PLEASANTON, Calif. , Aug. 28, 2025 /PRNewswire/ -- Movano Health (Nasdaq: MOVE )(the "Company") announced today that, by letter received on August 27, 2025 , the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq") has determined to grant the Company's request to continue its listing on Nasdaq, subject to (i) the Company regaining compliance with Listing Rule 5250(c)(1), requiring the timely filing of periodic reports (the "Period Filing Rule"), by filing its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025 on or before September 30, 2025, and (ii) the Company demonstrating compliance with Listing Rule 5550(a)(2), requiring the maintenance of $1.00 per share bid price (the "Bid Price Rule"), on or before October 30, 2025.
The Panel's determination follows a hearing on August 19, 2025 , at which the Panel considered the Company's plan to regain compliance with the Periodic Filing Rule and the Bid Price Rule. The Company has and continues to work diligently with its new auditor to complete and file with the Securities and Exchange Commission ("SEC") its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 , and June 30, 2025 , and expects to do so within the extension period granted by the Panel. Additionally, on August 19, 2025 , the Company filed a Preliminary Proxy Statement for its Annual Shareholders Meeting to be held on September 26, 2025 , at which the Company's shareholders will have the opportunity to approve a reverse stock split proposal, the effect of which will allow the Company to demonstrate compliance with the Bid Price rule within the extension period granted by the Panel.
About Movano Health
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring ( www.eviering.com ), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. Featuring modern and flexible form factors, Movano Health's devices offer an innovative approach to delivering trusted data to both customers and enterprises, capturing a comprehensive picture of an individual's health data and uniquely translating it into personalized and intelligent insights.
Movano Health's proprietary technologies and wearable medical device solutions will soon enable the use of data as a tool to proactively monitor and manage health outcomes across a number of patient populations that exist in healthcare. For more information on Movano Health, visit https://movanohealth.com/ .
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements relating to the Company's plan to regain compliance with Nasdaq's rules and the timing thereof. Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to the potential inability to meet Nasdaq's requirements within the extension period granted by the Nasdaq Panel? uncertainties associated with the Company's preparation of the delinquent filings? uncertainties associated with achieving the required shareholder vote necessary to approve a reverse stock split proposal and the possibility of additional delays in the filing of the delinquent filings and the Company's other SEC filings. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
SOURCE Movano
FAQ**
What specific actions is Movano Inc. (Nasdaq: MOVE) taking to ensure compliance with Nasdaq's Listing Rule 5250(c)(regarding periodic filing requirements by the September 30, 2025 deadline?
How does the proposed reverse stock split plan impact Movano Inc. (Nasdaq: MOVE)'s ability to meet the $1.00 bid price requirement under Listing Rule 5550(a)(by the October 30, 20deadline?
What are the potential risks involved for Movano Inc. (Nasdaq: MOVE) in meeting the compliance deadlines set by the Nasdaq Hearings Panel, particularly concerning its quarterly reports and the reverse stock split?
In what ways might the outcome of the upcoming shareholder vote on the reverse stock split affect the market perception and stock performance of Movano Inc. (Nasdaq: MOVE)?
**MWN-AI FAQ is based on asking OpenAI questions about Movano Inc. (NASDAQ: MOVE).
NASDAQ: MOVE
MOVE Trading
2.0% G/L:
$14.28 Last:
10,412 Volume:
$14.04 Open:
